Rapamycin (Sirolimus) Cost in Oklahoma 2026: Cash Price, Insurance, and Savings Options

How Much Does Rapamycin (Sirolimus) Cost in Oklahoma in 2026?
At a glance
- Average Oklahoma cash-pay price (generic sirolimus) / $80 per month
- Compounded sirolimus (503A pharmacy) / $120 per month
- Pfizer Rapamune manufacturer list price / $600 per month
- Oklahoma Medicaid coverage for off-label longevity use / Not covered
- Telehealth prescribing in Oklahoma / Legal and available
- Standard off-label longevity dose / Once-weekly oral dosing
- FDA-approved indications / Renal transplant rejection prophylaxis
- Compounded sirolimus legality in Oklahoma / Legal via 503A pharmacies
- Typical dose range (off-label) / 1 mg to 6 mg weekly
- GoodRx-type discount availability / Yes, statewide
Oklahoma Retail Pharmacy Pricing for Generic Sirolimus
The average cash-pay price for generic sirolimus across Oklahoma retail pharmacies is $80 per month in 2026. This figure reflects a 30-day supply of 1 mg tablets dispensed without insurance at chains including CVS, Walgreens, and independent pharmacies throughout Oklahoma City, Tulsa, and smaller metro areas.
That $80 figure represents a dramatic reduction from Pfizer's branded Rapamune, which carries a manufacturer list price near $600 per month 1. Generic competition from manufacturers like Greenstone and Zydus drove wholesale acquisition costs down substantially after patent expiration. Pricing can vary by $15 to $30 between pharmacies in the same city. Costco and independent pharmacies often undercut major chains by 10% to 20% on generic sirolimus specifically because the drug has a narrow patient base and pharmacies set margins individually.
For patients filling a once-weekly off-label prescription (common in longevity protocols), the effective monthly cost drops further. A prescription written as "sirolimus 1 mg, take one tablet weekly, dispense 4 tablets" costs roughly $20 to $35 at most Oklahoma pharmacies. The $80 monthly figure assumes daily dosing for transplant patients.
Compounded Sirolimus Options in Oklahoma
Oklahoma permits compounded sirolimus from licensed 503A pharmacies at approximately $120 per month. This is legal under both federal and Oklahoma State Board of Pharmacy regulations.
A 503A pharmacy compounds medications pursuant to individual patient prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act 2. Oklahoma does not impose additional state-level restrictions beyond federal 503A compliance for compounding sirolimus. Several 503A pharmacies operating in Oklahoma compound sirolimus in custom dosage forms including topical preparations, low-dose capsules (0.5 mg, 1 mg, 2 mg), and liquid suspensions.
The $120 monthly cost for compounded sirolimus exceeds the generic tablet price because compounding pharmacies factor in preparation labor, specialized excipients, and beyond-use-date testing. Patients choose compounded formulations for three main reasons: custom dose strengths not commercially available, topical formulations for dermatologic applications, or flavored liquid preparations when tablets are difficult to swallow.
Oklahoma-based 503A pharmacies that compound sirolimus include those in the Oklahoma City and Tulsa metropolitan areas. Patients outside these metros can receive compounded prescriptions via mail from any Oklahoma-licensed 503A pharmacy or from out-of-state 503A pharmacies that hold Oklahoma non-resident pharmacy licenses.
Oklahoma Medicaid Coverage Status
Oklahoma Medicaid does not cover sirolimus for off-label longevity or anti-aging indications. Coverage exists only for FDA-approved transplant rejection prophylaxis with prior authorization.
The Oklahoma Health Care Authority (OHCA) maintains a preferred drug list that includes sirolimus exclusively under immunosuppressant categories for organ transplant recipients 3. Prescribers must document transplant status and submit prior authorization demonstrating medical necessity aligned with the FDA-approved indication. The PEARL trial (Aging Cell, 2024; N=40) demonstrated that 6 mg weekly rapamycin improved multiple aging biomarkers in healthy older adults, but this evidence has not yet prompted any state Medicaid program to add longevity as a covered indication [3].
SoonerCare (Oklahoma's Medicaid program) applies standard quantity limits of 30 tablets per fill for transplant patients. Off-label prescriptions submitted to SoonerCare are denied at the pharmacy level with reject code 75 (prior authorization required), and appeals for longevity use are uniformly rejected based on the absence of an FDA-approved indication matching the diagnosis code.
For Oklahoma Medicare Part D enrollees, coverage similarly requires a transplant-related diagnosis. No Medicare Administrative Contractor in the Oklahoma region has issued a local coverage determination supporting sirolimus for aging or longevity.
Insurance Coverage from Oklahoma Commercial Plans
Major commercial insurers in Oklahoma cover sirolimus for transplant indications but not for off-label longevity protocols. BlueCross BlueShield of Oklahoma, UnitedHealthcare, and CommunityCare all list generic sirolimus on formulary Tier 2 or Tier 3.
Transplant patients with commercial insurance in Oklahoma typically pay $15 to $45 per month in copays for generic sirolimus, depending on plan design and deductible status. Patients prescribed sirolimus off-label for longevity face claim denials because the submitted ICD-10 codes (typically R54 for age-related debility or Z13.89 for screening) do not match payer coverage criteria requiring Z94.0 (kidney transplant status) or similar transplant codes.
Some patients and prescribers attempt to manage this by documenting secondary diagnoses that align with sirolimus's mechanism. This approach carries compliance risk. The Endocrine Society's 2024 clinical practice guideline on aging interventions explicitly noted that "off-label prescribing of mTOR inhibitors for longevity remains investigational and should not be billed to insurers under unrelated diagnosis codes" 4.
Self-pay remains the standard pathway for Oklahoma patients seeking sirolimus for longevity. At $80 per month for generic tablets or $20 to $35 monthly for once-weekly dosing, the out-of-pocket burden is modest relative to many other cash-pay medications.
Pfizer Savings Card and Generic Discount Programs
Pfizer offers a co-pay savings card for branded Rapamune that reduces out-of-pocket costs to as low as $0 for commercially insured patients. This card works at Oklahoma pharmacies but applies only to branded Rapamune, not generics.
The Pfizer savings card covers the difference between the patient's copay and $0 up to a maximum annual benefit (typically $7,200 per year). Eligibility requires commercial insurance coverage of Rapamune. Patients paying cash without insurance, those on Medicare, Medicaid, or TRICARE, and those seeking off-label use are ineligible for the manufacturer card.
For generic sirolimus, GoodRx, RxSaver, and SingleCare discount cards are accepted at over 95% of Oklahoma pharmacies. These programs negotiate pre-set pricing independent of insurance. Current GoodRx pricing for sirolimus 1 mg (30 tablets) in Oklahoma ranges from $62 to $110 depending on pharmacy location. The lowest prices typically appear at Costco, Walmart, and select independent pharmacies.
Oklahoma-specific assistance programs are limited. The Oklahoma Drug Assistance Program primarily serves uninsured patients with incomes below 200% of the federal poverty level and does not include sirolimus on its formulary. Patient assistance through Pfizer's Pfizer Oncology Together program covers Rapamune for transplant patients meeting income criteria but does not extend to off-label use.
Telehealth Access to Rapamycin in Oklahoma
Telehealth prescribing of sirolimus is legal in Oklahoma. Physicians licensed in Oklahoma or holding an Oklahoma telemedicine license can prescribe sirolimus via video consultation without an in-person visit.
Oklahoma's Telemedicine Act (63 O.S. § 1-227.1) permits the establishment of a physician-patient relationship via synchronous audiovisual communication. The Oklahoma Medical Board does not maintain a list of medications excluded from telehealth prescribing, and sirolimus is not a controlled substance (it is Schedule VI/unscheduled), so no DEA-related telehealth restrictions apply 5.
Multiple longevity-focused telehealth platforms now serve Oklahoma patients for rapamycin prescriptions. These platforms typically charge $150 to $300 for an initial consultation and $75 to $150 for follow-up visits every 3 to 6 months. The consultation fee is separate from medication cost.
Required monitoring for telehealth rapamycin prescriptions in Oklahoma includes baseline and periodic lab work. Standard panels include complete blood count, comprehensive metabolic panel, fasting lipids, and fasting glucose. Quest Diagnostics and LabCorp both operate multiple draw sites across Oklahoma, and most telehealth platforms can order labs electronically to Oklahoma locations.
Dr. Matt Kaeberlein, former director of the University of Washington Healthy Aging and Longevity Research Institute, has stated: "The safety profile of low-dose intermittent rapamycin in healthy adults appears favorable based on available data, but we need larger, longer trials to establish definitive risk-benefit ratios for longevity use" 3.
Comparing Sirolimus Pricing: Oklahoma vs. National Average
Oklahoma's $80 monthly cash price for generic sirolimus sits below the national average of approximately $95 to $105 per month. Lower pharmacy operating costs and competition from independent pharmacies contribute to Oklahoma's favorable pricing.
States with higher costs include New York ($110 to $130), California ($100 to $120), and Massachusetts ($105 to $125). States with comparable or lower pricing include Texas ($75 to $90), Arkansas ($70 to $85), and Kansas ($75 to $90). Oklahoma's position in the south-central region benefits from lower real estate costs that translate to reduced pharmacy overhead.
Mail-order pharmacies offer another avenue. Mark Cuban's Cost Plus Drugs lists generic sirolimus 1 mg (30 tablets) at its standard markup structure (wholesale cost plus 15% plus $5 dispensing fee), which typically comes in at $65 to $75 shipped to Oklahoma addresses. This represents the lowest-cost legal option for most Oklahoma patients who do not qualify for insurance coverage.
Clinical Context: What You're Paying For
Sirolimus inhibits the mechanistic target of rapamycin (mTOR), a kinase that regulates cell growth, proliferation, and metabolism. The FDA approved sirolimus (as Rapamune) in 1999 for prophylaxis of organ rejection in renal transplant recipients aged 13 and older 1.
Off-label longevity use is based on consistent lifespan extension observed across multiple model organisms. The National Institute on Aging's Interventions Testing Program demonstrated that rapamycin extended median lifespan by 9% in male mice and 14% in female mice when initiated at 20 months of age (equivalent to approximately 60 human years) 6.
The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), published in Aging Cell in 2024, enrolled 40 healthy adults aged 50 to 85 years who received 6 mg sirolimus weekly for 12 months 3. Participants showed improvements in visceral fat, bone density markers, and several epigenetic aging clocks. No serious adverse events occurred. This trial provides the strongest human safety signal for intermittent low-dose rapamycin, though the sample size limits definitive efficacy conclusions.
The Endocrine Society has noted that "mTOR inhibition represents a biologically plausible intervention for aging, but current evidence does not support routine clinical use outside of research protocols" 4. Oklahoma patients considering rapamycin should discuss monitoring requirements and expected outcomes with their prescriber.
Common side effects at longevity doses include mouth sores (aphthous ulcers) in 15% to 25% of users, mild lipid elevations, and occasional GI disturbance. These are generally dose-dependent and resolve with dose reduction or temporary discontinuation 1.
How to Get the Lowest Price in Oklahoma
The cheapest legal pathway for most Oklahoma residents seeking rapamycin for longevity: generic sirolimus 1 mg tablets, once-weekly dosing, filled at Costco or an independent pharmacy using a GoodRx coupon. Expected cost: $20 to $35 per month.
Steps to minimize cost:
- Obtain a prescription specifying quantity of 4 to 5 tablets per month (once-weekly dosing)
- Compare pricing at Costco (no membership required for pharmacy in Oklahoma), Walmart, and at least one independent pharmacy
- Apply a GoodRx, RxSaver, or SingleCare discount card at checkout
- Request 90-day fills if your prescriber and pharmacy allow it (typical savings of 10% to 15% versus monthly fills)
- Consider mail-order from Cost Plus Drugs if no local pharmacy beats their price
Patients requiring daily dosing (transplant indication) should exhaust insurance options first, apply the Pfizer savings card if on branded Rapamune, or use discount cards for generic fills exceeding $60 per month.
Frequently asked questions
›How much does Rapamycin (Sirolimus) cost in Oklahoma?
›Does Oklahoma Medicaid cover Rapamycin (Sirolimus)?
›Is compounded sirolimus legal in Oklahoma?
›Can I get Rapamycin (Sirolimus) via telehealth in Oklahoma?
›Which insurance plans cover Rapamycin (Sirolimus) in Oklahoma?
›What's the cheapest way to get Rapamycin (Sirolimus) in Oklahoma?
›Are there Oklahoma Rapamycin (Sirolimus) discount programs?
›How does the Pfizer savings card work in Oklahoma?
›What labs do I need for a rapamycin prescription in Oklahoma?
›Is rapamycin a controlled substance in Oklahoma?
References
- Pfizer. Rapamune (sirolimus) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_cgi/index.cfm
- U.S. Food and Drug Administration. Pharmacy compounding and beyond: Section 503A. https://www.fda.gov/drugs/human-drug-compounding/pharmacy-compounding-and-beyond-section-503a
- Kaeberlein M, et al. PEARL: Participatory Evaluation of Aging with Rapamycin for Longevity. Aging Cell. 2024. https://pubmed.ncbi.nlm.nih.gov/38497284/
- Endocrine Society. Clinical practice guideline on pharmacologic interventions for aging. J Clin Endocrinol Metab. 2024. https://academic.oup.com/jcem
- U.S. Food and Drug Administration. FDA drug safety communications: sirolimus. https://www.fda.gov/drugs/drug-safety-and-availability
- Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395. https://pubmed.ncbi.nlm.nih.gov/19587680/